Announced
Synopsis
NeoGenomics, a network of clinical laboratories, agreed to acquire Inivata, a biotechnology company, from Schroder, a closed-ended investment company, or $390m. "We are exercising our option to purchase Inivata eight months ahead of plan at what we believe is an attractive value in today's M&A marketplace for liquid biopsy companies. We are delighted to welcome Inivata's world class team of liquid biopsy experts and talented employees to NeoGenomics," Mark Mallon, NeoGenomics CEO.
Principals
Show Details & Financials
Did you work on this deal?
Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.
By continuing, you agree to our Terms & Conditions and our Data Privacy Policy
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.